Bausch Health Downgraded To Neutral From Overweight At Piper Sandler

Healthcare Text Screenshot Near Green Fern Leaf

Image Source: Pexels

Piper Sandler analyst David Amsellem downgraded Bausch Health (BHC) to Neutral from Overweight with a price target of $30, up from $25.

With the shares up 25% year-to-date, the analyst took a fresh look at the two entities that will be created as a result of the split of Bausch into a stand-alone eye care business and a pharmaceutical business.

The visibility into the sustainability of cash flows for remaining company "gives us pause," Amsellem tells investors in a research note. As such, the analyst does not envision "major value creation from current levels."

Disclaimer: TheFly's news is intended for informational purposes only and does not claim to be actionable for investment decisions. Read more at  more

How did you like this article? Let us know so we can better customize your reading experience.


Leave a comment to automatically be entered into our contest to win a free Echo Show.